Compounds and compositions for the treatment of MPNST

Abstract

The present invention relates to pharmaceutical combinations comprising an SHP2 inhibitor and a CDK4 / 6 inhibitor; pharmaceutical compositions comprising same; and methods of using such combinations and compositions in the treatment or prevention of conditions, where an SHP2 inhibitor in combination with CDK4 / 6 inhibition is beneficial, for example, in the treatment of NF-1 associated MPNST.

Description

[Technical field]

[0001] The present invention relates to SHP2 inhibitors, pharmaceutical combinations comprising an SHP2 inhibitor and a CDK4 / 6 inhibitor, and pharmaceutical combinations comprising a MEK inhibitor and a CDK4 / 6 inhibitor; pharmaceutical compositions comprising the same; and methods of using such compounds, combinations and compositions in the treatment of conditions, where SHP2 inhibition or CDK4 / 6 inhibition in combination with SHP2 inhibition or MEK inhibition is beneficial, for example, in the treatment of malignant peripheral nerve sheath tumors (MPNST). [Background technology]

[0002] Malignant peripheral nerve sheath tumors (MPNSTs) are rare aggressive soft tissue sarcomas with high unmet clinical need, especially when metastatic or unresectable. No standard treatment exists for this indication, although soft tissue sarcoma chemotherapy regimens may offer limited benefit. MPNSTs may arise sporadically (approximately 45%), in association with neurofibromatosis type 1 (approximately 45%), or in association with prior radiation therapy (approximately 10%). Neurofibromatosis type 1 (NF1) is a common neurogenetic syndrome characterized by neurocognitive effects, a predisposition to develop benign and malignant tumors, cutaneous and other physical findings, and, in 30-50% of patients, plexiform neurofibromas (pNFs). pNFs are precursor tumors to their malignant counterparts, malignant peripheral nerve sheath tumors (MPNSTs), and as such can be a significant cause of pain, disfigurement, and functional impairment.

[0003] TNO155 is an orally available allosteric inhibitor of Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2, encoded by the PTPN11 gene), which transmits signals from activated receptor tyrosine kinases (RTKs) to downstream pathways, including the extracellular signal-regulated kinase (ERK) pathway. SHP2 has also been implicated in immune checkpoint and cytokine receptor signaling. TNO155 has demonstrated efficacy in a broad range of RTK-dependent human cancer cell lines and in vivo tumor xenografts.

[0004] Cyclin D protein is important in cancer cell division and promotes cell cycle progression from G1 to S phase by forming a complex with CDK4 and CDK6 protein kinases to hyperphosphorylate and activate retinoblastoma protein (Rb). Ribociclib inhibits CDK4 / 6-specific phosphorylation of Rb, thereby arresting cell cycle progression in G1 phase. Cyclin D1 is an effector of downstream signaling of mutant EGFR and other RTKs, suggesting that the cyclin D1-CDK4 / 6 axis plays an important role in proliferation downstream of RTKs.

[0005] SHP2 inhibition, a combination of SHP2 and CDK4 / 6 inhibitors, or a combination of CDK4 / 6 and MEK inhibitors are effective in MPNST and produce durable responses, which represents a novel treatment approach for patients with metastatic or unresectable MPNST. Summary of the Invention

[0006] The present invention provides SHP2 inhibitors for the treatment of metastatic or unresectable MPNST.

[0007] In another embodiment, the present invention provides (a) SHP2 inhibitors and (b) CDK4 / 6 inhibitors for the treatment of MPNST The present invention provides a pharmaceutical composition comprising:

[0008] In another embodiment, the present invention provides (a) CDK4 / 6 inhibitors and (b) MEK inhibitors for the treatment of MPNST The present invention provides a pharmaceutical composition comprising:

[0009] Either combination of SHP2i+CDK4 / 6i or CDK4 / 6i+MEKi will be referred to herein as a "combination of the invention."

[0010] In another embodiment of the combination of the invention, the SHP2i+CDK4 / 6i or CDK4 / 6i+MEKi are in the same formulation.

[0011] In another embodiment of the combination of the invention, the SHP2i+CDK4 / 6i or CDK4 / 6i+MEKi are in separate formulations.

[0012] In another embodiment, the combination of the present invention is for simultaneous or sequential administration (in any order).

[0013] In another embodiment, a method of treating MPNST (sporadic MPNST, or NF1-associated MPNST, or MPNST associated with radiation therapy) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of any combination of SHP2i, or SHP2i+CDK4 / 6i, or CDK4 / 6i+MEKi.

[0014] In a further embodiment, the combination of any of SHP2i or SHP2i+CDK4 / 6i or CDK4 / 6i+MEKi provides for use in the manufacture of a medicament for treating MPNST (sporadic MPNST, or NF1-associated MPNST or MPNST associated with radiation therapy) in a patient in need thereof.

[0015] In another embodiment is a pharmaceutical composition comprising a combination of the invention.

[0016] In a further embodiment, the pharmaceutical composition further comprises one or more pharma- ceutically acceptable excipients. [Brief description of the drawings]

[0017] [Figure 1] 4 shows results for the combination of SHP2i (TNO155) + CDK4 / 6i (ribociclib) in PDX models JH-2-031, WU-225, WU-386, WU-545, JH-2-079, and JH-2-002. [Diagram 2]4 shows results for the combination of a CDK4 / 6i (ribociclib) and a MEKi (trametinib) in PDX models JH-2-031, WU-225, WU-386, WU-545 and JH-2-079. [Diagram 3] Results are shown (as a heatmap) for the combination of CDK4 / 6i (ribociclib) + SHP2i (TNO155) in 10 naturally occurring NF1-MPNST cell lines and two trametinib-resistant cell lines (ST8814Res and NF90.8Res). [Figure 4] 1 shows results for the combination of CDK4 / 6i (ribociclib) + SHP2i (TNO155) in 11 NF1-MPNST cell lines. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] definition The general terms used hereinbefore and hereinafter preferably have, unless otherwise stated, the following meanings within the context of the present disclosure, and whenever used, the more general terms may, independently of each other, be replaced by more specific definitions or remain as they are to define more specific embodiments of the invention.

[0019] The term "treat" or "treatment" as used herein includes treatment that alleviates, alleviates, or relieves at least one symptom in a patient, or results in a delay in the progression of a disease. For example, treatment can be a decrease in one or several symptoms of a disorder, such as NF-1-associated MPNST, or a complete eradication of the disorder. Within the meaning of this disclosure, the term "treat" also refers to inhibiting, delaying the onset (i.e., the period prior to clinical signs of the disease) and / or reducing the risk of developing or worsening a disease.

[0020] The terms "including" and "including" are used herein in an open-ended and non-limiting sense, unless otherwise indicated.

[0021] The terms "a," "an," and "the," and similar references in the context of describing the present invention (especially in the context of the claims which follow) should be construed to encompass both the singular and the plural, unless otherwise stated herein or clearly contradicted by context. When the plural is used for compounds, salts, etc., this is taken to mean a single compound, salt, etc.

[0022] The term "combination therapy" or "in combination with" refers to the administration of two or more therapeutic agents to treat a condition or disorder described in the present disclosure (e.g., sporadic MPNST or NF1-associated MPNST or MPNST associated with radiation therapy). Such administration includes co-administration of these therapeutic agents at about the same time, such as in a single capsule with a fixed ratio of active ingredients. Alternatively, such administration includes co-administration in multiple containers for each active ingredient, or in separate containers (e.g., capsules, powders, and liquids). The powders and / or liquids can be reconstituted or diluted to the desired dose prior to administration. Furthermore, such administration also includes the use of each type of therapeutic agent at about the same time or sequentially at different times. In either case, the treatment regimen provides the beneficial effect of the drug combination in treating the condition or disorder described herein.

[0023] Combination therapy can provide a "synergistic effect" and be "synergistic", i.e., the effect obtained when the active ingredients are used together is greater than the sum of the effects obtained from using the compounds separately. Synergistic effects can be obtained when the active ingredients are (1) formulated and administered simultaneously or delivered simultaneously in a combined unit dosage form; (2) delivered alternately or in parallel as separate formulations; or (3) delivered by some other regimen. When delivered in alternating therapy, synergistic effects can be obtained when the compounds are administered or delivered sequentially, for example, by different injections in separate syringes. Generally, during alternating therapy, an effective dosage of each active ingredient is administered sequentially, i.e., sequentially, whereas in combination therapy, effective dosages of two or more active ingredients are administered together.

[0024] The term "pharmaceutical combination" as used herein refers to either a fixed combination in one dosage unit form, or a non-fixed combination or kit of parts for combined administration, where two or more therapeutic agents can be administered independently, either simultaneously or separately within time intervals, particularly those time intervals that allow the combination partners to exhibit a synergistic effect, e.g., a synergistic effect.

[0025] The term "SHP2i" includes, but is not limited to, TNO155, JAB-3068, JAB-3312, RMC-4630 (or any SHP2 inhibitor contained in U.S. Pat. No. 10,590,090), RLY-1971, BBP-398 (IACS-15509), ERAS-601, and PF-07284892 (ARRY-558).

[0026] The term "CDK4 / 6i" includes, but is not limited to, ribociclib, palbociclib, and abemaciclib.

[0027] The term "MEKi" includes, but is not limited to, trametinib, cobimetinib, binimetinib, mirdametinib, and selumetinib.

[0028] The term "synergistic effect" as used herein refers to the effect of two therapeutic agents, e.g., the compound TNO155 as an SHP2 inhibitor and ribociclib as a CDK4 / 6 inhibitor, in slowing the symptomatic progression of, e.g., NF-1 associated MPNST, or disease symptoms thereof, that is greater than the simple addition of the effects of each drug administered by itself. Synergistic effects can be calculated, for example, using appropriate methods, such as the Sigmoid-Emax formula (Holford, NHG and Scheiner, LB, Clin. Pharmacokinet. 6:429-453 (1981)), the Loewe additivity formula (Loewe, S. and Muischnek, H., Arch. Exp. Pathol Pharmacol. 114:313-326 (1926)), and the median-effect formula (Chou, TC and Talalay, P., Adv. Enzyme Regul. 22:27-55 (1984)). Each of the above-mentioned formulas can be used on experimental data to generate corresponding graphs to help evaluate the effect of drug combinations. The corresponding graphs associated with the above-mentioned formulas are the concentration-effect curve, the isobologram curve, and the combination index curve, respectively.

[0029] The specific combination of the present invention, for example, TNO155 and ribociclib, is also intended to represent unlabeled forms of the compound as well as isotopically labeled forms. Isotopically labeled compounds have one or more atoms replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into TNO155 and ribociclib include isotopes of hydrogen, carbon, nitrogen, oxygen, and chlorine, for example: 2 H, 3 H, 11 C. 13 C. 14 C. 15 N, 35 S, 36 The present invention includes isotopically labeled TNO155 and ribociclib, for example, those that contain a radioisotope, e.g. 3 H and 14 C, or non-radioactive isotopes, e.g. 2H and 13 C. Isotopically labeled TNO155 and ribociclib were used in metabolic studies ( 14 C), reaction rate studies (e.g. 2 H or 3 H), detection or imaging techniques such as positron emission tomography (PET) or single photon emission computed tomography (SPECT) (including drug or substrate tissue distribution assays), or radiotherapy of patients. 18 F-labeled LSZ102 may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art, or by processes similar to those described in the accompanying Examples using suitable isotopically labeling reagents.

[0030] Furthermore, the heavier isotopes, especially deuterium (i.e. 2 Substitution with heavier isotopes (H or D) may provide certain therapeutic advantages due to greater metabolic stability, such as increased in vivo half-life, reduced dosage requirements, or improved therapeutic index. It is understood that deuterium is considered a substituent of TNO155 or ribociclib in this context. The concentration of such heavier isotopes, specifically deuterium, may be defined by an isotopic enrichment factor. As used herein, the term "isotopic enrichment factor" refers to the ratio between the abundance of an isotope and the natural abundance of the specified isotope. If a substituent in TNO155 or ribociclib is designated as deuterium, such compounds have an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).

[0031] Description of Specific Embodiments In one embodiment, a method of treating malignant peripheral nerve sheath tumors comprising administering to a patient in need thereof a therapeutically effective amount of an SHP2 inhibitor.

[0032] In further embodiments, the malignant peripheral nerve sheath tumor is metastatic, unresectable, sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

[0033] In further embodiments, the SHP2 inhibitor is selected from TNO155, SHP099, JAB-3068, JAB-3312, RMC-4630 (or any SHP2 inhibitor contained in U.S. Pat. No. 10,590,090), RLY-1971, BBP-398 (IACS-15509), ERAS-601, and PF-07284892 (ARRY-558).

[0034] In a further embodiment, the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof.

[0035] In a further embodiment, the pharmaceutical salt is a succinate salt.

[0036] In further embodiments, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally at a dose of about 1.5 mg / day, or 3 mg / day, or 6 mg / day, or 10 mg / day, or 20 mg / day, or 30 mg / day, or 40 mg / day, or 50 mg / day, or 60 mg / day, or 70 mg / day, or 80 mg / day, or 90 mg / day, or 100 mg / day.

[0037] In further embodiments, the dosing schedule is selected from consecutive, 2 weeks on / 1 week off, or 3 weeks on / 1 week off.

[0038] In another embodiment, a method of treating malignant peripheral nerve sheath tumors, comprising administering to a patient in need thereof a pharmaceutical composition comprising: (a) an SHP2 inhibitor; and (b) a CDK4 / 6 inhibitor.

[0039] In further embodiments, the malignant peripheral nerve sheath tumor is sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

[0040] In further embodiments, the SHP2 inhibitor is selected from TNO155, SHP099, JAB-3068, JAB-3312, RMC-4630 (or any SHP2 inhibitor contained in U.S. Pat. No. 10,590,090), RLY-1971, BBP-398 (IACS-15509), ERAS-601, and PF-07284892 (ARRY-558).

[0041] In a further embodiment, the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof.

[0042] In further embodiments, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally at a dose of about 1.5 mg / day, or 3 mg / day, or 6 mg / day, or 10 mg / day, or 20 mg / day, or 30 mg / day, or 40 mg / day, or 50 mg / day, or 60 mg / day, or 70 mg / day, or 80 mg / day, or 90 mg / day, or 100 mg / day.

[0043] In a further embodiment, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally once daily and the dosing schedule is selected from consecutive 2 weeks on / 1 week off or 3 weeks on / 1 week off.

[0044] In a further embodiment, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally once daily on a schedule of 2 weeks on and 1 week off.

[0045] In a further embodiment, the CDK4 / 6 inhibitor is selected from ribociclib, palbociclib, and abemaciclib.

[0046] In a further embodiment, the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or a pharma- ceutically acceptable salt thereof.

[0047] In further embodiments, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at a dose of about 100 mg / day, or 200 mg / day, or 300 mg / day, or 400 mg / day, or 500 mg / day, or 600 mg / day.

[0048] In a further embodiment, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at 600 mg for 21 days followed by 7 days off.

[0049] In another embodiment, a method of treating malignant peripheral nerve sheath tumors, comprising administering to a patient in need thereof a pharmaceutical composition comprising: (a) a MEK inhibitor; and (b) a CDK4 / 6 inhibitor.

[0050] In further embodiments, the malignant peripheral nerve sheath tumor is sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

[0051] In further embodiments, the MEKi is selected from trametinib, cobimetinib, binimetinib, mirdametinib, and selumetinib.

[0052] In a further embodiment, the MEK inhibitor is N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide, or a pharma- ceutically acceptable salt thereof.

[0053] In further embodiments, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide is administered and dimethylsulfoxide is administered orally at doses of about 0.5, 1, 1.5 and 2 mg per day.

[0054] In a further embodiment, the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or a pharma- ceutically acceptable salt thereof.

[0055] In further embodiments, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at a dose of about 100 mg / day, or 200 mg / day, or 300 mg / day, or 400 mg / day, or 500 mg / day, or 600 mg / day.

[0056] In a further embodiment, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at 600 mg for 21 days followed by 7 days off.

[0057] In another embodiment, the present invention provides a method for the treatment of MPNST (sporadic MPNST or NF1 associated or radiation therapy associated MPNST) comprising administering to the patient a compound of the structure: [ka] or a pharma- ceutically acceptable salt thereof.

[0058] In another embodiment, the present invention provides a method for the treatment of MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST), (a) Structure: [ka] or a pharma- ceutically acceptable salt thereof; and (b) Structure: [ka] or a pharma- ceutical acceptable salt thereof. The present invention provides a pharmaceutical composition comprising:

[0059] In another embodiment, the present invention provides a method for the treatment of MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST), (a) Structure: [ka] or a pharmaceutically acceptable salt thereof; and (b) Structure: [ka] or a pharma- ceutically acceptable salt or solvate thereof. The present invention provides a pharmaceutical composition comprising:

[0060] In one embodiment, a method of treating MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST) comprising administering to a patient in need thereof a pharmaceutical composition comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof.

[0061] In another embodiment, a method of treating MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST) comprising administering to a patient in need thereof a pharmaceutical composition comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof, in combination with a second therapeutic agent.

[0062] In further embodiments, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof, and the second therapeutic agent are administered simultaneously, separately, or over a period of time.

[0063] In a further embodiment, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof, administered to a patient in need thereof is effective in treating MPNST (sporadic MPNST or MPNST associated with NF1 or associated with radiation therapy).

[0064] In a further embodiment, the method includes a second therapeutic agent.

[0065] In a further embodiment, the amount of (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof, and a second therapeutic agent administered to a subject in need thereof is effective to treat MPSNT (sporadic MPNST or MPNST associated with NF1 or associated with radiation therapy).

[0066] In a further embodiment, the second therapeutic agent is a CDK4 / 6 inhibitor.

[0067] In a further embodiment, the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or a pharma- ceutically acceptable salt thereof.

[0068] In further embodiments, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally at a dose of about 1.5 mg / day, or 3 mg / day, or 6 mg / day, or 10 mg / day, or 20 mg / day, or 30 mg / day, or 40 mg / day, or 50 mg / day, or 60 mg / day, or 70 mg / day, or 80 mg / day, or 90 mg / day, or 100 mg / day.

[0069] In a further embodiment, (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine is administered orally at a daily dose of 20 mg in a 21 day cycle of 2 weeks on medication followed by 1 week off medication.

[0070] In further embodiments, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at a dose of about 100 mg / day, or 200 mg / day, or 300 mg / day, or 400 mg / day, or 500 mg / day, or 600 mg / day.

[0071] In a further embodiment, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at 200 mg for 21 days.

[0072] In a further embodiment, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at 300 mg for 21 days followed by 7 days off.

[0073] In a further embodiment, 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide is administered orally at 600 mg for 21 days followed by 7 days off.

[0074] In another embodiment, a method of treating MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST) comprising administering to a patient in need thereof a pharmaceutical composition comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutical acceptable salt thereof, in combination with ribociclic to overcome MEKi (trametinib) resistance.

[0075] In another embodiment, a method of treating MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST) comprising administering to a patient in need thereof a pharmaceutical composition comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutical acceptable salt thereof, in combination with ribociclib for MPNST patients who have received MEK inhibitor treatment for a previous benign tumor neurofibroma and have developed acquired resistance.

[0076] In another embodiment, a method of treating MPNST (sporadic MPNST or NF1-associated or radiation therapy-associated MPNST) comprising administering to a patient in need thereof a pharmaceutical composition comprising (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof, in combination with ribociclib for MPNST patients exhibiting intrinsic resistance to MEK inhibitors.

[0077] Pharmacology and Usefulness Neurofibromatosis type 1 (NF1) is one of the most common inherited tumor predisposition syndromes affecting 1 in every 2500-3000 individuals worldwide. Affected individuals are therefore born with one inactivated copy (germline mutation) and one functional copy of the NF1 gene in every cell in the body. The presence of a germline mutation increases the risk of tumor formation, which requires only somatic loss of the remaining functional NF1 gene.

[0078] NF1 is characterized by neurocognitive effects, a predisposition to develop benign and malignant tumors, skin and other physical findings, and, in 30-50% of patients, plexiform neurofibromas (pNFs). pNFs are precursors to their malignant counterparts, malignant peripheral nerve sheath tumors (MPNSTs), and as such can be a significant cause of pain, disfigurement, and functional disability. The overall lifetime risk of transformation from pNF to MPNST approaches 10%, and NF1 patients develop MPNST at a significantly younger age than patients with spontaneous MPNST.

[0079] MPNST is a rare aggressive soft tissue sarcoma with high unmet clinical need, especially when metastatic or unresectable. There is no standard treatment for this indication, but soft tissue sarcoma chemotherapy regimens may offer limited benefit. Challenges associated with treating patients with MPNST include their relative insensitivity to conventional systemic chemotherapy and radiation therapy, and their propensity to metastasize. The only known curative treatment for MPNST is surgical resection with wide negative margins, which is often not feasible due to location or size, surgery-related morbidity, or the presence of distant metastases. Despite many clinical trials of chemotherapy and targeted agents, there has been little progress in overall patient survival. A retrospective pooled analysis of 12 trials in which various such regimens were used as initial treatment (i.e., first-line therapy) demonstrated a response rate of 21%, a median progression-free survival of 17 weeks, and a median overall survival of 48 weeks. Given the limited benefit of chemotherapy, several molecular targeted therapies have been investigated in patients with MPNST with grim results. Recent clinical trials of such agents have consistently yielded objective response rates of 0% and, when reported, median overall survival times have been approximately 4-5 months.

[0080] MPNSTs are commonly characterized by loss of the tumor suppressor NF1, and their incidence is higher in patients with the autosomal dominant NF1 germline loss cancer predisposition syndrome, neurofibromatosis type 1 (NF1). Patients with NF1 syndrome are estimated to have an 8-13% lifetime incidence of MPNST and an annual incidence of 1.6 per 1000 individuals, while the incidence of sporadic MPNST in the general population in the United States is 1.46 per million per year.

[0081] Among all MPNSTs, approximately 22-50% occur in patients with germline NF1 loss, while the rest occur sporadically. Prior radiation therapy is a risk factor for MPNST, with approximately 10% of MPNSTs occurring in this setting. The majority of all NF1-associated MPNSTs and MPNSTs occurring sporadically or in cases of prior radiation therapy are characterized by loss of NF1, and the second most commonly detected genetic alteration in each of these cases is loss of tumor suppressors. In patients with germline NF1 loss, loss of CDKN2A is thought to be an early step in malignant progression, occurring during the transition from benign plexiform neurofibroma to atypical neurofibroma, a precursor to MPNST.

[0082] Neurofibromin, the gene product of NF1, is a RAS GTPase-activating protein (RAS-GAP) involved in the hydrolysis of active RAS-GTP to inactive RAS-GDP. It is genetically altered in nearly 90% of MPNSTs. Thus, aberrant RAS activation underlies the pathogenesis of NF1-mutated cancers. However, it is not known whether a single RAS family member is the predominant RAS activated in NF1-deficient MPNSTs, nor is the degree of functional redundancy of the well-understood classical RAS family members HRAS, NRAS, and KRAS in this tumor type. Among the well-characterized RAS effector pathways are RAF / MEK / ERK, PI3K / AKT, and Ral-GDS signaling. Of these, ERK signaling is a key downstream effector, and therefore the concept of pharmacological MEK inhibition has been applied to models of MPNSTs. The MEK inhibitor (MEKi) selumetinib produces partial responses in 71% of children with NF1-associated pNF (NCT01362803). However, preclinical responses of MPNST to single-agent MEKi have been partial. This suggests the need for improved understanding of the role of ERK and other RAS effector pathways. Additional signaling pathways, including mTOR signaling, have been implicated in MPNST tumorigenesis, and pharmacological inhibition of these pathways has been proposed. Furthermore, inactivation of polycomb repressive complex-2 (PRC2) by loss of function (LOF) of SUZ12 or EED occurs recurrently and specifically in MPNST, but not in its benign counterpart pNF, and has been implicated in the amplification of RAS-driven transcription. Complex cooperation between inactivation of tumor suppressors and activation of oncogenic pathways is likely to occur in NF1-driven tumorigenesis, and inhibition of more than one RAS effector pathway may be necessary for a complete antitumor effect.

[0083] NF1 gene inactivation and loss of NF1 protein (neurofibromin) expression characterize the majority of NF1-MPNST. Although NF1 loss is necessary for MPNST development, it is not sufficient for malignant transformation. Approximately 50% of MPNST are sporadic (i.e., occurring in patients without germline NF1 loss and thus without NF1 syndrome). Most sporadic MPNST have somatic NF1 loss in the tumor.

[0084] Alterations in the TP53, CDKN2A, and EED / SUZ12 genes have been reported as cooperating secondary genetic alterations that promote MPNST development. However, molecular targeting of each of these LOF alterations presents its own challenges. Furthermore, transcriptional analysis studies revealed upregulated expression of cell cycle-promoting genes, including RABL6A, a negative regulator of RB1. Loss of CDKN2A (the gene encoding p16 INK4a), inactivation of RB, and hyperactivation of cyclin-dependent kinases (CDKs) suggest that small molecule CDK4 / 6 inhibitors (CDK4 / 6i) may be a therapeutic approach. However, monotherapy with CDK4 / 6i shows limited efficacy due to bypass mechanisms such as CDK2 hyperactivation and E2F amplification. Other studies suggest upregulation of cell cycle regulators Aurora kinase A (AURKA) and polo-like kinase (PLK1), but monotherapy with Aurora kinase or PLK1 inhibitors has a narrow therapeutic index, low in vivo antitumor activity, and no objective responses observed in clinical trials. Furthermore, combined CDK4 / 6i and MEKi have demonstrated synergistic effects in preclinical models of melanoma, neuroblastoma, and pancreatic and KRAS-mutated colorectal cancer. Given the dependency of D-cyclins on RAS signaling and the recurrent loss of CDKN2A in MPNST, the cytostatic action of CDK4 / 6i may be enhanced to induce apoptosis in MPNST together with drugs targeting downstream RAS signaling, such as upstream RTK / RAS regulators (SHP2) or ERK pathways (MEKi).

[0085] Single MEK inhibitors are not effective in MPNSTs, prompting the search for combination therapeutics using MEKi and agents targeting adaptively altered signaling elements that emerge upon short-term MEK inhibition. "Adaptive resistance" to MEK and other small molecule inhibitors involves dynamic changes in signaling networks and non-genomic bypass mechanisms that frequently occur through transcriptional induction of genes for receptor tyrosine kinases (RTKs) or their ligands, resulting in transient and partial responses. The inability to predict which RTKs will be significantly upregulated as a signaling adaptation to MEKi is a challenge in designing MEKi+RTKi combination therapy.

[0086] In the case of NF1 loss, the RAS-MAPK pathway, a well-established oncogenic driver, is hyperactivated due to this impairment of RAS inactivation. SHP2 is a cytoplasmic phosphatase involved in RAS GTP loading, which accelerates the transition of RAS from an inactive GDP-bound state to an active GTP-bound state. Thus, inhibition of SHP2 is predicted to counter the RAS-activating effects of NF1 loss.

[0087] Therefore, an approach is needed to simultaneously target the signaling node that represents the convergence point from upstream RTK signaling together with the inhibition of RAS effector pathways, and PTPN11 / SHP2 phosphatase represents such a promising target. SHP2 is a central node in RTK reactivation and MEKi-driven adaptive resistance in multiple cancer models. SHP2 phosphatase promotes RAS-GEF-mediated RAS-GTP loading, accelerating the transition of RAS from an inactive GDP-bound state to an active GTP-bound state and its recruitment to the plasma membrane, and is therefore required for RAS / ERK pathway activation by most RTKs when RTK activation occurs. SHP2 inhibition counters the RAS-activating effect of NF1 loss. NF1 is involved in the inactivation of RAS, whereas SHP2 is involved in the activation of RAS.

[0088] Therefore, SHP2 inhibition (SHP2i) and combination SHP2i may be an approach to overcome signaling adaptation to MEKi in tumors with hyperactive RAS due to loss of NF1, for example. To identify optimal therapeutic approaches to effectively target NF1-associated MPNSTs, there is a need to design rational combination therapies that inhibit inhibitor-induced pathway reactivation.

[0089] TNO155 is a first-in-class allosteric inhibitor of wild-type SHP2. SHP2 is a ubiquitously expressed non-receptor protein tyrosine phosphatase (PTP) composed of two N-terminal SH2 domains, a classical PTP domain, and a C-terminal tail. The phosphatase activity is autoinhibited by the two SHP2 domains binding to the PTP domain (closed conformation). Upon receptor tyrosine kinase (RTK) activation, SHP2 is recruited to the plasma membrane where it binds to activated RTKs and several adaptor proteins to relay signaling by activating the RAS / ERK pathway. TNO155 binds to the inactive or "closed" conformation of SHP2, thereby preventing it from opening to the active conformation. This prevents signaling from activated RTKs to the downstream RAS / ERK pathway.

[0090] TNO155 has demonstrated efficacy in a wide range of RTK-dependent human cancer cell lines and in vivo xenografts. SHP2 inhibition can be measured by assessing biomarkers within the ERK signaling pathway, such as reduced levels of phosphorylated ERK1 / 2 (pERK) and downregulation of dual specificity phosphatase 6 (DUSP6) mRNA transcripts. In KYSE-520 (esophageal squamous cell carcinoma) and DETROIT-562 (pharyngeal squamous cell carcinoma) cancer cell lines, the in vitro pERK IC50 was 8 nM (3.4 ng / mL) and 35 nM (14.8 ng / mL), respectively, and the anti-proliferative IC50 was 100 nM (42.2 ng / mL) and 470 nM (198.3 ng / mL), respectively. The anti-proliferative effect of TNO155 was shown to be most effective in cancer cell lines that are dependent on RTK signaling. In vivo, SHP2 inhibition with orally administered TNO155 (20 mg / kg) achieved approximately 95% reduction in DUSP6 mRNA transcripts and 47% regression in the EGFR-dependent DETROIT-562 cancer cell line when administered on a twice-daily schedule. Dose fractionation studies indicate that maximal efficacy is achieved when 50% PD inhibition is reached for at least 80% of dosing intervals, combined with modulation of tumor DUSP6 biomarkers. Given the extensive crosstalk between the ERK pathway and the CDK4 / 6 complex in cancer cells, the combination of TNO155 with the selective CDK4 / 6 inhibitor, ribociclib, was explored.

[0091] Ribociclib (LEE011, Kisqali®) is an orally bioavailable, highly selective, small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 / 6). Ribociclib has been approved by several health authorities, including the United States Food and Drug Administration (USFDA) and the European Commission, as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) based on a randomized, double-blind, placebo-controlled international clinical trial (MONALEESA-2 [CLEE011A2301]). On July 18, 2018, the USFDA expanded the indication of ribociclib in combination with an AI as initial endocrine-based therapy to include premenopausal / perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. Indications have also expanded to include ribociclib in combination with fulvestrant for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, either as initial endocrine-based therapy or after disease progression on endocrine therapy (MONALEESA-7 [CLEE011E2301] and MONALEESA-3 [CLEE011F2301], respectively). Further marketing approvals in HR-positive, HER2-negative advanced or metastatic breast cancer are under consideration by health authorities around the world. Further Phase III clinical trials for the treatment of patients with HR-positive breast cancer, as well as several other Phase I or Phase II clinical trials, are ongoing.

[0092] Ribociclib exhibits a high degree of selectivity for CDK4 / 6 over other cyclin-dependent kinases, with IC values ​​of 0.01 and 0.039 μM, respectively, in biochemical assays. 50Ribociclib inhibits the CDK4 / cyclin D1 and CDK6 / cyclin D3 enzyme complexes at 100-fold increase in phosphorylation of Rb and prevents cell cycle progression from G1 to S phase in over 40 Rb-positive cell lines derived from diverse cancer types. In contrast, no effect of ribociclib on cell cycle progression was observed in lineage-matched Rb-negative cell lines.

[0093] Ribociclib has demonstrated in vivo antitumor activity in a subset of tumor xenograft models, including, but not limited to, breast malignancies, melanoma, neuroblastoma, malignant rhabdoid, lung, pancreatic, and hematological malignancies. Additionally, ribociclib has demonstrated antitumor activity when combined with targeted agents that inhibit signaling pathways known to regulate cyclin D levels, including inhibitors of the RAF, mitogen-activated protein kinase kinase (MEK), phosphoinositide 3-kinase (PI3K), and mammalian target of rapamycin (mTOR) pathways.

[0094] TNO155 is currently being investigated in combination with ribociclib in study CTNO155B12101.

[0095] Current treatment options for NF1-MPNST are limited, with surgery and radiation therapy for localized disease to reduce the risk of local recurrence. Only prospective studies using cytotoxic chemotherapy have demonstrated a response rate of approximately 17% (5 / 29 subjects) after doxorubicin and ifosfamide treatment in patients with NF1, suggesting that MPNST responds minimally to chemotherapy. Similar responses have been reported with a variety of chemotherapeutic agents for metastatic disease. Furthermore, many molecular targeted therapies that were highly effective in mouse Nf1 MPNST preclinical trials have proven ineffective when translated into human clinical trials. The poor translation of preclinical findings to the clinic is likely to reflect two major barriers: (1) current preclinical models do not reflect the extent of genetic heterogeneity observed in human MPNST, and (2) treatments may show variable efficacy based on molecular subtypes that are not currently captured using monogenic models. By generating patient-derived models, the range of molecular subtypes of MPNST can be better characterized to determine how different MPNST respond to therapeutic approaches.

[0096] To address this critical issue, a series of patient-derived MPNST xenografts were generated that more broadly reflect the genetic heterogeneity seen in the human condition. The preference to generate PDX lines instead of conventional cell lines was guided by two scientific principles. First, PDX lines have been shown to reflect the original tumor at earlier passages. Second, PDX lines are thought to be less subject to genetic drift than conventional cell lines, in part because they are not grown on plastic and adapted to growth outside of a host.

[0097] Example 1 below uses generated NF1-MPNST patient-derived xenograft (PDX) lines grown in immunodeficient NRG or NSG mice. They harbor germline and somatic NF1 mutations, as well as the range of genomic alterations seen in patients with NF1, including loss of CDKN2A, TP53 mutations, EED / SUZ12 mutations, and many copy number alterations. Preclinical data presented in Example 1 below provides evidence that the combination of the SHP2 inhibitor, TNO155, and the CDK4 / 6 inhibitor, ribociclib, exerts a combinatorial effect in NF-1-associated MPNST.

[0098] Pharmaceutical Compositions In another aspect, the present invention provides a pharma- ceutically acceptable composition comprising a therapeutically effective amount of TNO155 and ribociclib, formulated together with one or more pharma- ceutically acceptable carriers (excipients) and / or diluents. As described in detail below, the pharmaceutical compositions of the present invention may be specially formulated for administration in solid or liquid form, including those adapted for oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets, such as those intended for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue.

[0099] As used herein, the phrase "therapeutically effective amount" means an amount of a compound, material, or composition, including a compound of the invention, effective to produce some desired therapeutic effect in at least a subpopulation of cells in an animal, at a reasonable benefit / risk ratio applicable to any medical treatment.

[0100] The phrase "pharmacologically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals, within the scope of sound medical judgment, without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0101] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricants, talc, magnesium stearate, calcium stearate, or zinc stearate, or stearic acid), or solvent that encapsulates a material involved in the transport or delivery of a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the patient. Some examples of materials which can serve as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; and (10) glycols. (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffer solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; and (22) other non-toxic compatible substances used in pharmaceutical compounding.

[0102] As presented above, certain embodiments of the compounds may contain basic functional groups, such as amino or alkylamino groups, and thus pharma- ceutically acceptable salts can be formed with pharma-ceutically acceptable acids. The term "pharma-ceutically acceptable salts" in this respect refers to the relatively non-toxic inorganic and organic acid addition salts of the compounds of the present invention. The salts can be prepared in situ in the administration vehicle or during the dosage form manufacturing process, or by separately reacting the purified compounds of the present invention in their free base form with a suitable organic or inorganic acid and isolating the salt thus formed during subsequent purification. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate (see, e.g., Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).

[0103] Pharmaceutically acceptable salts of the subject compounds include conventional non-toxic salts of the compounds, for example, from non-toxic organic or inorganic acids, or quaternary ammonium salts. For example, such conventional non-toxic salts include those derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, etc.; and salts prepared from organic acids, such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, etc. For example, a pharma-ceutically acceptable salt of TNO155 is the succinate salt.

[0104] In other cases, the compounds of the present invention may contain one or more acidic functional groups, and thus pharma- ceutically acceptable salts can be formed with pharma-ceutically acceptable bases. The term "pharma-ceutically acceptable salts" in this case refers to the relatively non-toxic inorganic and organic base addition salts of the compounds of the present invention. The salts can also be prepared in situ in the administration vehicle or in the dosage form manufacturing process, or by separately reacting the purified compound in its free acid form with a suitable base, such as a hydroxide, carbonate, or bicarbonate salt of a pharma-ceutically acceptable metal cation, with ammonia, or with a pharma-ceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for forming base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, and piperazine, and the like (see, for example, Berge et al., supra).

[0105] Additionally, wetting agents, emulsifying agents, and lubricating agents, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring, and perfuming agents, preservatives, and antioxidants can be present in the composition.

[0106] The formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary depending on the host to be treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will usually be that amount of the compound that produces a therapeutic effect. Usually, out of one hundred percent, this amount will range from about 0.1 percent to about 99 percent of the active ingredient, preferably from about 5 percent to about 70 percent, and most preferably from about 10 percent to about 30 percent.

[0107] In certain embodiments, a formulation of the invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents such as bile acids, and polymeric carriers such as polyesters and polyanhydrides; and a compound of the invention. In certain embodiments, the above-described formulation renders the compound of the invention orally bioavailable.

[0108] Methods of preparing the formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0109] Compositions of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (with a flavored base, usually sucrose and gum arabic or gum tragacanth), powder, granules, as a solution, suspension, or solid dispersion in an aqueous or non-aqueous liquid, as an oil-in-water or water-in-oil liquid emulsion, as an elixir or syrup, as a troche (with an inert base, such as gelatin and glycerin, or sucrose and gum arabic), as a mouthwash, and the like, each containing a predetermined amount of a compound of the present invention as the active ingredient. The compounds of the present invention may also be administered as a bolus, electuary, or paste.

[0110] In the solid dosage forms of the invention for oral administration (capsules, tablets, pills, dragees, powders, granules, trouches, etc.), the active ingredient is mixed with one or more pharma- ceutically acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or gum arabic; (3) humectants, such as glycerol; (4) disintegrants, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as glycerol, glycerol, or glycerol-based disintegrants ... glycerol, glycerol, glycerol, glycer (6) absorption enhancers, such as quaternary ammonium compounds and surfactants, such as poloxomers and sodium lauryl sulfate; (7) wetting agents, such as cetyl alcohol, glycerol monostearate, and nonionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) release-controlling agents, such as crospovidone or ethylcellulose. In the case of capsules, tablets, and pills, the pharmaceutical compositions may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard shell gelatin capsules using such excipients as lactose or milk sugar, and high molecular weight polyethylene glycols, and the like.

[0111] Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface-active agents, or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0112] Tablets and other solid dosage forms of the pharmaceutical composition of the present invention, such as dragees, capsules, pills, and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may also be formulated to achieve sustained or controlled release of the active ingredient, for example, using hydroxypropylmethylcellulose, other polymer matrices, liposomes, and / or microspheres, in various proportions to achieve the desired release profile. They may also be formulated for rapid release, for example, by lyophilization. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of a sterile solid composition that can be dissolved in sterile water or some other sterile injectable medium immediately before use. The compositions may also optionally contain opacifying agents, and may be of a composition that releases the active ingredient only, or preferentially, in a certain part of the digestive tract, or in some case delayed manner. Examples of embedding compositions that may be used include polymeric substances and waxes. The active ingredient may also be in microencapsulated form, if appropriate, with one or more of the excipients described above.

[0113] The liquid dosage form for oral administration of the compound of the present invention includes pharmaceutically acceptable emulsion, microemulsion, solution, suspension, syrup and elixir.In addition to active ingredient, liquid dosage form may contain inert diluent commonly used in the art, such as water or other solvent, solubilizer and emulsifier, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oil (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid ester of sorbitan, and mixtures thereof.

[0114] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0115] Suspensions may contain, in addition to the active compound, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.

[0116] Examples of suitable aqueous and non-aqueous carriers that may be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, and the like) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0117] The composition may also contain adjuvants, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms on the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, and phenol sorbic acid. It may also be desirable to include isotonic agents, such as sugars and sodium chloride, in the composition.

[0118] When the compound of the present invention is administered to a patient as a medicine, it may be administered as it is, or may be administered in combination with a pharma- ceutical carrier as a pharmaceutical composition containing, for example, 0.1 to 99% (more preferably 10 to 30%) of an active ingredient.

[0119] The compounds of the present invention (which may be used in a suitable hydrated form), and / or pharmaceutical compositions of the present invention are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those skilled in the art.

[0120] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied so as to provide for a particular patient, composition, and mode of administration an amount of the active ingredient which is effective to achieve the desired therapeutic response without being toxic to the patient.

[0121] The selected dosage level will depend on a variety of factors, including the activity of the particular compound of the invention, or esters, salts, or amides thereof, being used, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being used, the rate and extent of absorption, the duration of treatment, other drugs, compounds, and / or materials used in combination with the particular compound being used, the age, sex, weight, symptoms, health, and prior medical history of the patient being treated, as well as factors well known in the medical art.

[0122] A physician of ordinary skill in the art can easily determine and prescribe the effective amount of the pharmaceutical composition required. For example, a physician could start a dose of the compound of the present invention used in the pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0123] In general, a suitable daily dose of the combination of this invention will be that amount of each compound that is the lowest dose effective to produce a therapeutic effect. Such effective amounts will generally depend on the factors described above.

[0124] In another aspect, the present invention provides pharma- ceutically acceptable compositions comprising a therapeutically effective amount of one or more of the subject compounds, as described above, formulated together with one or more pharma- ceutically acceptable carriers (excipients) and / or diluents. EXAMPLES

[0125] TNO155, ribociclib and trametinib (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (TNO155) is synthesized according to Example 69 of WO 2015 / 107495. 7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide (ribociclib) is synthesized according to Example 74 of WO 2010 / 020675. N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide (trametinib) is synthesized according to Example 4-1 of WO 2005 / 121142. WO 2015 / 107495, WO 2010 / 020675 and WO 2005 / 121142 / are incorporated herein by reference in their entireties.

[0126] SHP2, MEK and CDK4 / 6 are key nodes in RAS effector signaling in MPNSTs, and combinations of inhibitors of these molecules may have synergistic antitumor activity. The in vivo antitumor efficacy and toxicity of TNO155 monotherapy and combination therapy (TNO155+ribociclib), (ribociclib+trametinib) in PDX models were tested (Example 1).

[0127] Example 1 Efficacy of TNO155 Single Agent and Combination of TNO155 + Ribociclib or Ribociclib and Trametinib in NF1-MPNST Patient-Derived Xenograft (PDX) Models The PDX model of Example 1 was generated and characterized according to Dehrner, et al., JCI Insight 2021;6(6):e146351 and Pollard, K., et al., Sci Data, 2020;7:184. NRG (NOD-Rag1null IL2rg null , NOD rag γ) mice are used for all experiments.

[0128] SHP2i (TNO155 (A) 7.5 mg / kg) and CDK4 / 6i (ribociclib (B) 75 mg / kg, once daily (5 days per week) at a RP2D of half-human equivalent) and MEKi (trametinib (C) 0.075 mg / kg or 0.15 mg / kg, once daily) were administered to NRG mice by oral gavage. Tumor response, survival and toxicity data were collected and analyzed. To form tumors, 1-2 million NF1-MPNST PDX-derived cells (JH-2-031, JH-2-079, JH-2-002, WU-225, WU-386, or WU-545) in 50% Matrigel (BD Biosciences) were subcutaneously injected into 4-6 week old female NRG mice. Tumors were measured and mice were weighed twice weekly once tumors began to form. 3 Drugs were administered starting when the tumor volume reached 100 μg / kg. Mice were treated with vehicle, single agent (A or B or C) or combination (A+B or B+C) for up to 42 days. Each group consisted of 3-5 mice. Tumor volume was calculated according to the formula: V=L×W 2 Calculations were performed using (π / 6), where L=longest diameter and W=width.

[0129] FIG. 1 shows results for the combination of SHP2i (TNO155) + CDK4 / 6i (ribociclib) in PDX models JH-2-031, WU-225, WU-386, WU-545, JH-2-079 and JH-2-002.

[0130] FIG. 2 shows results for the combination of a CDK4 / 6i (ribociclib) and a MEKi (trametinib) in PDX models JH-2-031, WU-225, WU-386, WU-545 and JH-2-079.

[0131] The combination effect was evident in the five in vivo PDXs tested. Some PDX models demonstrated similar responses to SHP2i alone or SHP2i + CDK4 / 6i during the first 4 weeks of treatment, but more sustained growth inhibition was found to result from the combination. Pharmacological investigations in WU-386 tumors collected 4 hours after the treatment endpoint (4 weeks) from each cohort demonstrated reduced p-ERK levels in tumors treated with either SHP2i alone or the SHP2i / CDK4 / 6i combination, with the combination resulting in higher p-ERK inhibition than TNO155. This demonstrates that the combined inhibition of SHP2 and CDK4 / 6 is effective in a patient-derived model of NF1-associated MPNST, produces sustained responses, and is a novel treatment approach for patients with MPNST.

[0132] Example 2 In vitro analysis of TNO155 single agent and TNO155 + ribociclib combination in naturally occurring NF1-MPNST cell lines and trametinib-resistant lines Ten native NF1-MPNST cell lines (ST8814Par, NF90.8Par, S462, NF96.2, NF10.1, NF11.1, JH-2-002, JH-2-031, JH-2-079 and JH-2-103) and two trametinib-resistant lines (ST8814Res and NF90.8Res) were treated with DMSO, TNO155 (0.3, 1 and 3 μM), ribociclib (1 and 3 μM) or combinations thereof for approximately one week. Cell numbers were counted using a trypan blue dye exclusion assay (Sigma-Aldrich) and normalized to DMSO control. Figure 3 shows the results as a heat map. Ten native NF1-MPNST cell lines showed partial sensitivity to single-agent TNO155, and deeper responses were observed with the combination of TNO155 + ribociclib compared to TNO155 alone. Single-agent TNO155 was found to have limited activity, but combination effects were seen in two MEKi-resistant cell line models.

[0133] Example 3 In vitro analysis of TNO155 single agent and TNO155 + ribociclib combination in naturally occurring NF1-MPNST cell lines and trametinib-resistant lines Eleven NF1-MPNST cell lines were treated with DMSO, TNO155 (0.3, 1 and 3 μM), ribociclib (1 and 3 μM) or their combinations for approximately 2 weeks. Cells were washed with PBS, fixed with 10% neutral buffered formalin, and then stained with 0.1% crystal violet. Figure 4 shows that TNO155 and ribociclib have a combinatorial effect in several NF1-MPNST cell lines.

[0134] The combination of TNO155 and ribociclib was investigated in in vitro cell line models of MPNST as well as in vivo patient-derived xenograft (PDX) MPNST models. In cell line models, antitumor activity was observed with both single agents, which was enhanced in combination (see Figures 1-4). Mechanistically, the combination of TNO155 and ribociclib resulted in reduced ERK signaling and CDK4-cyclin D1 activity compared to either drug alone. In in vivo patient-derived xenograft (PDX) models of NF1-associated MPNST, TNO155 showed considerable antitumor activity as a single agent, which was enhanced in some models by the addition of ribociclib. In vitro and in vivo observations indicate that the combined use of TNO155 and ribociclib can produce deeper and more durable responses and overcome MEKi (trametinib) resistance. The combination of TNO155 and ribociclib may be a potential treatment approach for MPNST patients who have received MEK inhibitor treatment for a previous benign tumor neurofibroma and developed acquired resistance, as well as for MPNST patients who show intrinsic resistance to MEK inhibitors.

[0135] It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in view thereof will be suggested to those skilled in the art, and can be included within the spirit and scope of this application and the appended claims.

Claims

1. A pharmaceutical composition comprising a therapeutically effective amount of an SHP2 inhibitor for treating malignant peripheral nerve sheath tumors.

2. 2. The pharmaceutical composition of claim 1, wherein the malignant peripheral nerve sheath tumor is metastatic, unresectable, sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

3. 2. The pharmaceutical composition of claim 1, wherein the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 1, wherein the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, and the SHP2 inhibitor is orally administered at a dose of about 1.5 mg / day, or 3 mg / day, or 6 mg / day, or 10 mg / day, or 20 mg / day, or 30 mg / day, or 40 mg / day, or 50 mg / day, or 60 mg / day, or 70 mg / day, or 80 mg / day, or 90 mg / day, or 100 mg / day.

5. The pharmaceutical composition of claim 1, wherein the administration schedule is selected from a consecutive schedule of 2 weeks on / 1 week off or 3 weeks on / 1 week off.

6. A combination comprising: (a) an SHP2 inhibitor; and (b) a CDK4 / 6 inhibitor for treating malignant peripheral nerve sheath tumor.

7. 7. The method of claim 6, wherein the malignant peripheral nerve sheath tumor is sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

8. 7. The combination of claim 6, wherein the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine, or a pharma- ceutically acceptable salt thereof.

9. The combination of claim 6, wherein the SHP2 inhibitor is (3S,4S)-8-(6-amino-5-((2-amino-3-chloropyridin-4-yl)thio)pyrazin-2-yl)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine and the SHP2 inhibitor is administered orally at a dose of about 1.5 mg / day, or 3 mg / day, or 6 mg / day, or 10 mg / day, or 20 mg / day, or 30 mg / day, or 40 mg / day, or 50 mg / day, or 60 mg / day, or 70 mg / day, or 80 mg / day, or 90 mg / day, or 100 mg / day.

10. The combination of claim 6, wherein the administration schedule is selected from consecutive, 2 weeks on / 1 week off or 3 weeks on / 1 week off.

11. 7. The combination of claim 6, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or a pharma- ceutically acceptable salt thereof.

12. The combination of claim 6, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and the CDK4 / 6 inhibitor is administered orally at a dose of about 100 mg / day, or 200 mg / day, or 300 mg / day, or 400 mg / day, or 500 mg / day, or 600 mg / day.

13. The combination of claim 6, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and the CDK4 / 6 inhibitor is administered orally at 600 mg for 21 days, followed by a 7-day break.

14. A combination comprising: (a) a MEK inhibitor; and (b) a CDK4 / 6 inhibitor for treating malignant peripheral nerve sheath tumors.

15. 15. The combination of claim 14, wherein the malignant peripheral nerve sheath tumor is sporadic, associated with neurofibromatosis type 1, or associated with radiation therapy.

16. 15. The combination of claim 14, wherein the MEK inhibitor is N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide, or a pharma- ceutically acceptable salt thereof.

17. The combination of claim 14, wherein the MEK inhibitor is N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide and the daily dimethylsulfoxide is administered orally in doses of about 0.5, 1, 1.5 and 2 mg per day.

18. 15. The combination of claim 14, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide, or a pharma- ceutically acceptable salt thereof.

19. The combination of claim 14, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and the CDK4 / 6 inhibitor is administered orally at a dose of about 100 mg / day, or 200 mg / day, or 300 mg / day, or 400 mg / day, or 500 mg / day, or 600 mg / day.

20. The combination of claim 14, wherein the CDK4 / 6 inhibitor is 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide and the CDK4 / 6 inhibitor is administered orally at 600 mg for 21 days, followed by a 7-day rest period.

Images